Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085358
Status:
COMPLETED
Last Update Posted:
2019-07-22
First Post:
2004-06-10
Brief Title:
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel Carboplatin and Paclitaxel in Treating Patients With Stage II Stage III or Stage IV Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cavity Carcinoma Cancer
Sponsor:
Organization:
National Cancer Institute NCI
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
40
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: